Table 2.
Unadjusted and adjusted Cox proportional hazards regression evaluating the association of selected patient demographic, clinical characteristics, and receipt of hormone therapy and risk of death and progression-free survival in women with ER+/PR− breast cancer, treated between 2003 and 2017 and registered in NCDB
| Characteristic | Univariable | Multivariable | ||||||
|---|---|---|---|---|---|---|---|---|
| Hazard ratio | 95% CI | P value | Hazard ratio | 95% CI | P value | |||
| Hormone therapy | ||||||||
| No hormone therapy | Reference | – | – | – | Reference | – | – | – |
| Hormone therapy | 0.58 | 0.56 | 0.59 | < 0.001 | 0.59 | 0.57 | 0.60 | < 0.001 |
| Age, years | 1.05 | 1.05 | 1.05 | < 0.001 | 1.06 | 1.05 | 1.06 | < 0.001 |
| Patient race | ||||||||
| White | Reference | – | – | – | Reference | – | – | – |
| Black | 1.20 | 1.15 | 1.25 | < 0.001 | 1.25 | 1.19 | 1.30 | < 0.001 |
| Other/Unknown | 0.65 | 0.60 | 0.71 | < 0.001 | 0.79 | 0.73 | 0.87 | < 0.001 |
| Charlson score | ||||||||
| 0 | Reference | – | – | – | Reference | – | – | – |
| 1 | 1.77 | 1.71 | 1.83 | < 0.001 | 1.42 | 1.37 | 1.47 | < 0.001 |
| ≥ 2 | 3.55 | 3.36 | 3.75 | < 0.001 | 2.44 | 2.30 | 2.59 | < 0.001 |
| Insurance status | ||||||||
| Private | Reference | – | – | – | – | – | – | – |
| Medicare | 2.08 | 1.97 | 2.20 | < 0.001 | – | – | – | – |
| Medicaid | 2.77 | 2.96 | 2.85 | < 0.001 | – | – | – | – |
| Other/Unknown | 1.76 | 1.62 | 1.90 | < 0.001 | – | – | – | – |
| Income quartile | ||||||||
| Q1 | Reference | – | – | – | – | – | – | – |
| Q2 | 0.93 | 0.89 | 0.98 | 0.004 | – | – | – | – |
| Q3 | 0.86 | 0.82 | 0.90 | < 0.001 | – | – | – | – |
| Q4 | 0.67 | 0.64 | 0.70 | < 0.001 | – | – | – | – |
| Education quartile | ||||||||
| Q1 | Reference | – | – | – | – | – | – | – |
| Q2 | 0.97 | 0.92 | 1.01 | – | – | – | – | |
| Q3 | 0.91 | 0.88 | 0.96 | < 0.001 | – | – | – | – |
| Q4 | 0.72 | 0.69 | 0.75 | < 0.001 | – | – | – | – |
| Geographic setting | ||||||||
| Metropolitan | Reference | |||||||
| Urban | 1.10 | 1.06 | 1.14 | < 0.001 | – | – | – | – |
| Rural | 1.16 | 1.06 | 1.28 | 0.001 | – | – | – | – |
| Type of hospital | ||||||||
| Community | Reference | – | – | – | Reference | – | – | – |
| Academic/integrated network | 0.82 | 0.81 | 0.85 | < 0.001 | 0.92 | 0.89 | 0.95 | < 0.001 |
| Tumor stage | ||||||||
| Stage I | Reference | – | – | – | Reference | – | – | – |
| Stage II | 1.80 | 1.74 | 1.86 | < 0.001 | 2.03 | 1.96 | 2.10 | < 0.001 |
| Stage III | 4.03 | 3.90 | 4.18 | < 0.001 | 4.87 | 4.69 | 5.05 | < 0.001 |
| Stage IV | 11.54 | 10.93 | 12.18 | < 0.001 | 12.97 | 12.22 | 13.76 | < 0.001 |
| Metastatic disease at diagnosis | ||||||||
| No | Reference | – | – | – | – | – | – | – |
| Yes | 6.95 | 6.64 | 7.28 | < 0.001 | – | – | – | – |
| Lymphadenectomy | ||||||||
| No | Reference | – | – | – | – | – | – | – |
| Yes | 0.31 | 0.30 | 0.32 | < 0.001 | – | – | – | – |
| Margin status | ||||||||
| Negative | Reference | – | – | – | Reference | – | – | – |
| Positive | 2.08 | 1.99 | 2.17 | < 0.001 | 1.37 | 1.31 | 1.44 | < 0.001 |